Molecular mechanisms mediating anti-myeloma activity of proteasome inhibitor PS-341.

被引：0

作者：

Hideshima, T ^{[1
]}

Mitsiades, C ^{[1
]}

Akiyama, M ^{[1
]}

Hayashi, T ^{[1
]}

Chauhan, D ^{[1
]}

Richardson, PG ^{[1
]}

Schlossman, RL ^{[1
]}

Podar, K ^{[1
]}

Munshi, NC ^{[1
]}

Mitsiades, N ^{[1
]}

Anderson, KC ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA

来源：

BLOOD | 2002年 / 100卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3215

引用

页码：814A / 814A

页数：1

共 50 条

[1] Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341
Hideshima, T
Mitsiades, C
Akiyama, M
Hayashi, T
Chauhan, D
Richardson, P
Schlossman, R
Podar, K
Munshi, NC
Mitsiades, N
Anderson, KC
BLOOD, 2003, 101 (04) : 1530 - 1534
[2] Clinical pharmacology of the proteasome inhibitor PS-341.
Nix, DJ
Pien, C
Labutti, J
Madden, T
Adams, J
Elliott, P
CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3732S - 3732S
[3] Gene expression profiling in the prediction of response of multiple myeloma to the proteasome inhibitor PS-341.
Shaughnessy, J
Zhan, FH
McCastlain, K
Tian, EM
Tricot, G
BLOOD, 2002, 100 (11) : 390A - 390A
[4] A phase I pharmacodynamic study of the proteasome inhibitor PS-341.
Thomas, JP
Adjei, A
Ehrlichman, C
Geiger, P
Haas, A
Arzoomanian, R
Alberti, D
Marnocha, R
Binger, K
Volkman, J
Feierabend, C
Tutsch, K
Adams, J
Eliot, P
Wilding, G
CLINICAL CANCER RESEARCH, 2000, 6 : 4549S - 4549S
[5] Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341
Dharminder Chauhan
Guilan Li
Teru Hideshima
Klaus Podar
Reshma Shringarpure
Constantine Mitsiades
Nikhil Munshi
P Renee Yew
Kenneth C Anderson
Oncogene, 2004, 23 : 3597 - 3602
[6] Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341
Chauhan, D
Li, GL
Hideshima, T
Podar, K
Shringarpure, R
Mitsiades, C
Munshi, N
Yew, PR
Anderson, KC
ONCOGENE, 2004, 23 (20) : 3597 - 3602
[7] Combination of proteasome inhibitor PS 341 (Veleade®) with histone acetylase inhibitor (HDAC) PXD 101 shows superior anti-myeloma activity and inhibits osteoclastogenesis.
Lentzsch, S
Anderson, G
Li, CL
Belani, CP
Mapara, MY
Roodman, D
BLOOD, 2005, 106 (11) : 699A - 699A
[8] (-)-epigallocatechin-3-gallate (EGCG), green tea component, antagonize the anti-myeloma activity of proteasome inhibitor PS-341 by direct chemical interaction
Kim, Tae Young
Park, Jongmin
Oh, Bora
Min, Hyun Jung
Jeong, Tae-Sook
Lee, Jae Hoon
Park, Seung Bum
Lee, Dong Soon
BLOOD, 2007, 110 (11) : 287B - 288B
[9] The proteasome inhibitor PS-341 modulates VEGF secretion and activity in multiple myeloma.
Mitsiades, N
Mitsiades, CS
Poulaki, V
Fanourakis, G
Chauhan, D
Munshi, NC
Hideshima, T
Anderson, KC
BLOOD, 2002, 100 (11) : 815A - 815A
[10] The Hsp90 inhibitor 17-AAG sensitizes human leukemia cells to proteasome inhibitor PS-341.
Yao, Q
Kersey, JH
BLOOD, 2003, 102 (11) : 622A - 623A

← 1 2 3 4 5 →